Key Points
- CEO Daniel Faga sold shares: Faga sold 9,202 shares on Jan 7 at an average price of $45.11 for $415,102 and also sold 15,309 shares on Jan 5 at $43.26 for $662,267, leaving him with 466,787 shares valued at about $21.06 million (a 1.93% reduction after the Jan 7 sale).
- Multiple insider dispositions: Other insiders (including the CFO and senior executives) also sold shares in the same filing period, which could increase selling pressure and raise questions about insider conviction despite strong holdings by some insiders.
- Offsetting corporate positives: The company has a $100 million stock repurchase authorization (up to ~9.6% of stock), a UBS upgrade to "strong‑buy," and has filed to partially dismiss a GSK royalty claim—each a potential positive catalyst for the stock.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CFO Dennis Mulroy sold 1,908 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $45.11, for a total value of $86,069.88. Following the completion of the sale, the chief financial officer owned 17,667 shares in the company, valued at $796,958.37. The trade was a 9.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Dennis Mulroy also recently made the following trade(s):
- On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total transaction of $145,483.38.
- On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The shares were sold at an average price of $50.00, for a total transaction of $500,000.00.
- On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25.
AnaptysBio Trading Down 3.1%
Shares of NASDAQ:ANAB opened at $43.80 on Friday. The firm's 50 day moving average is $42.46 and its two-hundred day moving average is $31.30. The firm has a market capitalization of $1.21 billion, a P/E ratio of -15.53 and a beta of 0.32. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $52.47.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. Analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.
AnaptysBio declared that its board has initiated a stock buyback program on Friday, November 21st that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's board believes its stock is undervalued.
Key AnaptysBio News
Here are the key news stories impacting AnaptysBio this week:
- Positive Sentiment: UBS upgraded AnaptysBio to a "strong‑buy," which can drive retail and institutional buying interest and lift short‑term momentum. UBS upgrade / coverage note
- Positive Sentiment: AnaptysBio filed a partial motion to dismiss Tesaro/GSK’s anticipatory‑breach claim related to Jemperli royalties; a successful dismissal would reduce legal and royalty exposure and improve free‑cash‑flow prospects tied to that program. AnaptysBio seeks partial dismissal in GSK dispute
- Negative Sentiment: CEO Daniel Faga sold about $662k of stock (9,202 shares), a disclosed insider sale that can raise investor concerns about insider conviction even though his remaining stake is still large. CEO stock sale article
- Negative Sentiment: Other insiders (CFO Dennis Mulroy, Paul Lizzul, Eric Loumeau and others) also sold shares in the same filing period — several sizable dispositions that increase selling pressure and may temper the upside from analyst upgrades or legal wins. SEC Form 4 filings detail these trades. SEC Form 4 filings (insider sales)
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in ANAB. Assenagon Asset Management S.A. raised its holdings in AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company's stock worth $25,719,000 after acquiring an additional 822,975 shares during the period. Woodline Partners LP raised its position in AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company's stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. 683 Capital Management LLC lifted its position in shares of AnaptysBio by 155.6% during the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company's stock worth $11,100,000 after buying an additional 304,373 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in shares of AnaptysBio by 2.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company's stock valued at $11,588,000 after purchasing an additional 10,005 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of AnaptysBio by 145.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company's stock worth $11,343,000 after buying an additional 219,648 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of analysts have commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Guggenheim reaffirmed a "buy" rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wells Fargo & Company boosted their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the company an "overweight" rating in a research note on Wednesday, November 5th. Stifel Nicolaus reduced their target price on AnaptysBio from $80.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, December 11th. Finally, Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $60.40.
View Our Latest Report on ANAB
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
